Not finding it? Sign in to also search OpenAlex live.
-
Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)
Steffen Koschmieder, Susanne Isfort, Florian Heinrich Heidel, Andreas Hochhaus, Heiko Becker, Philipp Jakob Jost, +19 more
3citations
15 results